

Cuando la adherencia al tratamiento complica el manejo de una dermatitis atópica

Isaac Carrasco

DVM. PhD. Acreditado AVEPA en Dermatología. GPCertDerm.
PGCertDerm

Responsable del Servicio Dermatología de AniCura Glòries Hospital Veterinari (Barcelona)

Referencias:

1. Hensel P, Santoro D, Favrot C, Hill P, Griffin C. Canine atopic dermatitis: detailed guidelines for diagnosis and allergen identification. *BMC Vet Res.* 2015 Aug 11;11:196. doi: 10.1186/s12917-015-0515-5. PMID: 26260508; PMCID: PMC4531508.
2. Favrot C, Steffan J, Seewald W, Picco F. A prospective study on the clinical features of chronic canine atopic dermatitis and its diagnosis. *Vet Dermatol.* 2010 Feb;21(1):23-31. doi: 10.1111/j.1365-3164.2009.00758.x. PMID: 20187911.
3. Olivry T, Saridomichelakis M, Nuttall T, Bensignor E, Griffin CE, Hill PB; International Committee on Allergic Diseases of Animals (ICADA). Validation of the Canine Atopic Dermatitis Extent and Severity Index (CADESI)-4, a simplified severity scale for assessing skin lesions of atopic dermatitis in dogs. *Vet Dermatol.* 2014 Apr;25(2):77-85, e25. doi: 10.1111/vde.12107. Epub 2014 Jan 25. PMID: 24461108.
4. Eisenschenk MC, Hensel P, Saridomichelakis MN, Tamamoto-Mochizuki C, Pucheu-Haston CM, Santoro D. Introduction to the ICADA 2023 canine atopic dermatitis pathogenesis review articles and updated definition. *Vet Dermatol.* 2024 Feb;35(1):3-4. doi: 10.1111/vde.13183. Epub 2023 Dec 14. PMID: 38095285.
5. Marsella R. Advances in our understanding of canine atopic dermatitis. *Vet Dermatol.* 2021 Dec;32(6):547-e151. doi: 10.1111/vde.12965. Epub 2021 Apr 23. PMID: 33891338.
6. Gentry CM. Updates on the Pathogenesis of Canine and Feline Atopic Dermatitis: Part 1, History, Breed Prevalence, Genetics, Allergens, and the Environment. *Vet Clin North Am Small Anim Pract.* 2025 Mar;55(2):157-171. doi: 10.1016/j.cvsm.2024.11.001. Epub 2024 Dec 27. PMID: 39732548.
7. Santoro D, Marsella R, Pucheu-Haston CM, Eisenschenk MN, Nuttall T, Bizikova P. Review: Pathogenesis of canine atopic dermatitis: skin barrier and host-micro-organism interaction. *Vet Dermatol.* 2015 Apr;26(2):84-e25. doi: 10.1111/vde.12197. Epub 2015 Feb 13. PMID: 25683702.

8. Kobayashi T, Imanishi I. Epithelial-immune crosstalk with the skin microbiota in homeostasis and atopic dermatitis - a mini review. *Vet Dermatol.* 2021 Dec;32(6):533-e147. doi: 10.1111/vde.13007. Epub 2021 Aug 10. PMID: 34378246.
9. DeBoer DJ, Marsella R. The ACVD task force on canine atopic dermatitis (XII): the relationship of cutaneous infections to the pathogenesis and clinical course of canine atopic dermatitis. *Vet Immunol Immunopathol.* 2001 Sep 20;81(3-4):239-49. doi: 10.1016/s0165-2427(01)00345-2. PMID: 11553386.
10. Miller J, Simpson A, Bloom P, Diesel A, Friedeck A, Paterson T, Wisecup M, Yu CM. 2023 AAHA Management of Allergic Skin Diseases in Dogs and Cats Guidelines. *J Am Anim Hosp Assoc.* 2023 Nov 1;59(6):255-284. doi: 10.5326/JAAHA-MS-7396. PMID: 37883677.
11. Santoro D, Saridomichelakis M, Eisenschenk M, Tamamoto-Mochizuki C, Hensel P, Pucheu-Haston C; International Committee on Allergic Diseases of Animals (ICADA). Update on the skin barrier, cutaneous microbiome and host defence peptides in canine atopic dermatitis. *Vet Dermatol.* 2024 Feb;35(1):5-14. doi: 10.1111/vde.13215. Epub 2023 Nov 22. PMID: 37990608.
12. Fernandes B, Mendes AC, Alves SP, Schmidt V, Bizarro AF, Pinto M, Pereira H, Marto J, Lourenço AM. A Novel Topical Emollient Plus for Canine Atopic Dermatitis: A Clinical Trial Assessing Efficacy and User Acceptance. *Vet Dermatol.* 2025 Nov 6. doi: 10.1111/vde.70035. Epub ahead of print. PMID: 41194653.
13. Marsella R, Segarra S, Ahrens K, Alonso C, Ferrer L. Topical treatment with SPHINGOLIPIDS and GLYCOSAMINOGLYCANS for canine atopic dermatitis. *BMC Vet Res.* 2020 Mar 20;16(1):92. doi: 10.1186/s12917-020-02306-6. PMID: 32197613; PMCID: PMC7082980.
14. Majewska A, Gajewska M, Dembele K. Effect of Allergen-Specific Immunotherapy on Transcriptomic Changes in Canine Atopic Dermatitis. *Int J Mol Sci.* 2023 Jul 18;24(14):11616. doi: 10.3390/ijms241411616. PMID: 37511372; PMCID: PMC10380577.
15. Mueller RS. A systematic review of allergen immunotherapy, a successful therapy for canine atopic dermatitis and feline atopic skin syndrome. *J Am Vet Med Assoc.* 2023 Mar 24;261(S1):S30-S35. doi: 10.2460/javma.22.12.0576. PMID: 36940185.
16. Wichtowska A, Olejnik M. Anti-Cytokine Drugs in the Treatment of Canine Atopic Dermatitis. *Int J Mol Sci.* 2025 Nov 13;26(22):10990. doi: 10.3390/ijms262210990. PMID: 41303472; PMCID: PMC12652870.
17. Marsella R, Doerr K, Gonzales A, Rosenkrantz W, Schissler J, White A. Oclacitinib 10 years later: lessons learned and directions for the future. *J Am Vet Med Assoc.* 2023 Mar 25;261(S1):S36-S47. doi: 10.2460/javma.22.12.0570. PMID: 36944222.
18. Nederveld SM, Krautmann MJ, Mitchell J. Safety of the Selective JAK1 Inhibitor Oclacitinib in Dogs. *J Vet Pharmacol Ther.* 2025 May;48(3):135-145. doi: 10.1111/jvp.13503. Epub 2025 Feb 28. PMID: 40018984; PMCID: PMC12066884.
19. Jasiacka-Mikołajczyk A, Socha P. Treatment with oclacitinib, a Janus kinase inhibitor, down-regulates and up-regulates CD25 and Foxp3 expression, respectively, in peripheral blood T cells of dogs with atopic dermatitis. *BMC Vet Res.* 2024 Oct 26;20(1):489. doi: 10.1186/s12917-024-04340-0. PMID: 39462373; PMCID: PMC11515184.

20. Michels GM, Walsh KF, Kryda KA, Mahabir SP, Walters RR, Hoevers JD, Martinon OM. A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis. *Vet Dermatol.* 2016 Dec;27(6):505-e136. doi: 10.1111/vde.12364. Epub 2016 Sep 19. PMID: 27647513.
21. Bruet V, Mosca M, Briand A, Bourdeau P, Pin D, Cochet-Faivre N, Cadiergues MC. Clinical Guidelines for the Use of Antipruritic Drugs in the Control of the Most Frequent Pruritic Skin Diseases in Dogs. *Vet Sci.* 2022 Mar 22;9(4):149. doi: 10.3390/vetsci9040149. PMID: 35448647; PMCID: PMC9030482.
22. Kasper B, Zablotzki Y, Mueller RS. Long-term use of lokivetmab in dogs with atopic dermatitis. *Vet Dermatol.* 2024 Dec;35(6):683-693. doi: 10.1111/vde.13286. Epub 2024 Aug 14. PMID: 39143659.
23. Linek M, Favrot C. Impact of canine atopic dermatitis on the health-related quality of life of affected dogs and quality of life of their owners. *Vet Dermatol.* 2010 Oct;21(5):456-62. doi: 10.1111/j.1365-3164.2010.00899.x. Epub 2010 May 12. PMID: 20492625.
24. Noli C. Assessing Quality of Life for Pets with Dermatologic Disease and Their Owners. *Vet Clin North Am Small Anim Pract.* 2019 Jan;49(1):83-93. doi: 10.1016/j.cvsm.2018.08.008. Epub 2018 Sep 11. PMID: 30213532.
25. Tominaga M, Takamori K. Peripheral itch sensitization in atopic dermatitis. *Allergol Int.* 2022 Jul;71(3):265-277. doi: 10.1016/j.alit.2022.04.003. Epub 2022 May 25. PMID: 35624035.
26. Feld M, Garcia R, Buddenkotte J, Katayama S, Lewis K, Muirhead G, Hevezi P, Plessner K, Schrupf H, Krjutskov K, Sergeeva O, Müller HW, Tsoka S, Kere J, Dillon SR, Steinhoff M, Homey B. The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves. *J Allergy Clin Immunol.* 2016 Aug;138(2):500-508.e24. doi: 10.1016/j.jaci.2016.02.020. Epub 2016 Apr 6. PMID: 27212086.
27. Tamamoto-Mochizuki C, Paps JS, Olivry T. Proactive maintenance therapy of canine atopic dermatitis with the anti-IL-31 lokivetmab. Can a monoclonal antibody blocking a single cytokine prevent allergy flares? *Vet Dermatol.* 2019 Jan 23. doi: 10.1111/vde.12715. Epub ahead of print. PMID: 30672050.
28. Rybníček J, Lau-Gillard PJ, Harvey R, Hill PB. Further validation of a pruritus severity scale for use in dogs. *Vet Dermatol.* 2009 Apr;20(2):115-22. doi: 10.1111/j.1365-3164.2008.00728.x. Epub 2009 Dec 19. PMID: 19171021.